Expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 3, 2005, Pages 265-271

  Wolday, Dawit ^a   Tegbaru, Belete ^a   Kassu, Afework ^a   Messele, Tsehaynesh ^a   Coutinho, Roel ^b   Van Baarle, Debbie ^c   Miedema, Frank ^c  

^a Ethio Netherlands AIDS Research Project ENARP   (Ethiopia)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c SANQUIN RESEARCH   (Netherlands)

Author keywords

Africa; CCR5; CD4+ T cells; Chemokines; CXCR4; HIV; Tuberculosis

Indexed keywords

CD4 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ETHAMBUTOL; ISONIAZID; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PYRAZINAMIDE; RANTES; RIFAMPICIN; STROMAL CELL DERIVED FACTOR 1ALPHA;

ACID FAST BACTERIUM; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TUBERCULOSIS; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CHEMOKINES, CXC; HIV INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; MACROPHAGE INFLAMMATORY PROTEIN-1; RANTES; RECEPTORS, CCR5; RECEPTORS, CXCR4; TUBERCULOSIS, PULMONARY; VIREMIA; VIRUS REPLICATION;

EID: 21544438177     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000163027.47147.2e     Document Type: Article

References (52)

1. Barnes PF, Bloch AB, Davidson PT, et al. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1991;324:1644-1650.
2. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. N Engl J Med. 1992;326:231-235.
3. Whalen C, Horsburgh CR, Horn D, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med. 1995;151:129-135.
4. Rizzardini G, Trabattoni D, Saresella M, et al. Immune activation in HIV-infected African individuals. AIDS. 1998;12:2387-2396.
5. Messele T, Abdulkader M, Fontanet al, et al. Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts. Clin Exp Med. 1999;115:443-450.
6. Wolday D, Maayan S, Mariam ZG, et al. Immune activation in HIV-1-infected African patients correlates with high HIV RNA load [abstract]. Presented at: XIII International AIDS Conference; 2000; Durban, South Africa.
7. Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today. 1995;16: 187-191.
8. Vanham G, Edmonds K, Qing L, et al. Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection. Clin Exp Med. 1996;103:30-34.
9. 2-microglobulin in HIV-1-associated tuberculosis. J Infect Dis. 1993;167:43-48.
10. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol. 1996;157:1271-1278.
11. Lawn SD, Shattock RJ, Acheampong JW, et al. Sustained plasma TNF-α and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africa. AIDS. 1999;13:2231-2237.
12. Toossi Z, Sierra-Madero JG, Blinkhorn RA, et al. Enhanced susceptibility of blood monocytes from patients with pulmonary tuberculosis to productive infection with human immunodeficiency virus type-1. J Exp Med. 1993;177:1511-1516.
13. Lederman MM, Georges DL, Kusner DJ, et al. Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1994;7:727-733.
14. Zhang Y, Nakata K, Weiden M, et al. Mycobacterium tuberculosis enhances human immunodeficiency virus 1 replication by transcriptional activation at the long terminal repeat. J Clin Invest. 1995;95:2324-2331.
15. Toossi Z, Nicolacakis K, Xia L, et al. Activation of latent HIV-1 by Mycobacterium tuberculosis and its purified protein derivative in alveolar macrophages from HIV-infected individuals in vitro. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:325-331.
16. Majanja-Kizza H, Wajja A, Wu M, et al. Activation of β-chemokines and CCR5 in persons infected with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis. 2001;183:1801-1804.
17. Toossi Z, Johnson JL, Kanost RA, et al. Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. J Acquir Immune Defic Syndr. 2001;28:1-8.
18. Nakata K, Rom WN, Honda Y, et al. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med. 1997;155:996-1003.
19. Fraziano M, Cappelli G, Santucci M, et al. Expression of CCR5 is increased in human monocyte-derived macrophages and alveolar macrophages in the course of in vivo and in vitro Mycobacterium tuberculosis infection. AIDS Res Hum Retroviruses. 1999;15:869-874.
20. Orenstein JM, Fox C, Wahl SM. Macrophages as source of HIV during opportunistic infections. Science. 1997;276:1857-1861.
21. Wahl SM, Greenwell-Wild T, Peng G, et al. Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression. Proc Natl Acad Sci USA. 1998;95:12574-12579.
22. Jufffermans NP, Paxton WA, Dekkers PE, et al. Up-regulation of HIV coreceptors CXCR4 and CCR5 on CD4+ T cells during human endotoxemia and after stimulation with (myco)bacterial antigens: the role of cytokines. Blood. 2000;96:2649-2654.
23. Jufffermans NP, Speelman P, Verbon A, et al. Patients with active tuberculosis have increased expression of HIV coreceptors CXCR4 and CCR5 on CD4+ T cells. Clin Infect Dis. 2001;32:650-652.
24. Ostrowski MA, Justement SJ, Catanzaro A, et al. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol. 1998;161:3195-3201.
25. Kalinkovich A, Weisman Z, Leng Q, et al. Increased CCR5 expression with decreased β-chemokine secretion in Ethiopians: relevance to AIDS in Africa. J Hum Virol. 1999;2:283-289.
26. Clerici M, Butto S, Lukwiya M, et al. Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. AIDS. 2000;14:2083-2092.
27. Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Med. 2001;123: 233-238.
28. Archibald LK, den Dulk MO, Pallangayo KJ, et al. Fatal Mycobacterium tuberculosis bloodstream infections in febrile hospitalized adults in Dar es Salaam, Tanzania. J Infect Dis. 1998;26:290-296.
29. Dalgleish AG, Beverly PCL, Clapham PR, et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984;312:763-767.
30. Klatzmann D, Champagne E, Chamaret S, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 1984; 312:767-768.
31. Perelson AS, Neuman AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-1586.
32. Wolday D, Hailu B, Girma M, et al. Low CD4+ T-cell count and high HFV viral load precede the development of tuberculosis disease in a cohort of HIV-positive Ethiopians. Int J Tuberc Lung Dis. 2003;7:110-116.
33. Morris L, Martin DJ, Bredell H, et al. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis. 2003;187:1967-1971.
34. Stevenson M, Stanwick TL, Demsey MP, et al. HIV-1 replication is controlled at the level of T-cell activation and proviral integration. EMBO J. 1990;9:1551-1556.
35. Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry co-factor: functional cDNA cloning of a seven-transmembrane G protein coupled receptor. Science. 1996;272:872-877.
36. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381:667-673.
37. Deng HK, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381:661-666.
38. Alkhatib G, Combadiere C, Broder C, et al. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996;272:1955-1958.
39. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med. 1997;185:621-628.
40. Paxton WA, Kang S, Koup RA. The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression. AIDS Res Hum Retroviruses. 1998;14(Suppl 1):S89-S92.
41. Blaak H, Ran LJ, Rientsma R, et al. Susceptibility of in vitro stimulated PBMC to infection with NSI HIV-1 is associated with levels of CCR5 expression and β-chemokine production. Virology. 2000;267:237-246.
42. Sulkowski MS, Chaisson RE, Karp CL, et al. The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serological markers of immune activation among HIV-infected adults. J Infect Dis. 1998;178:1642-1648.
43. Hoffman IF, Jere CS, Taylor TE, et al. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS. 1999;13:487-494.
44. Berhe N, Wolday D, Hailu A, et al. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS. 1999;13: 1921-1925.
45. Lawn D, Karanja DMS, Mwinzi P, et al. The effect of treatment of schistosomiasis on blood plasma HIV-1 RNA concentration in coinfected individuals. AIDS. 2000;14:2437-2443.
46. Eyob G, Guebrexabher H, Lemma E, et al. Drug susceptibility of Mycobacterium tuberculosis in HIV-infected and -uninfected Ethiopians and its impact on outcome after 24 months of follow-up. Int J Tuberc Lung Dis. 2004;8:1388-1391.
47. Abebe A, Kuiken CL, Goudsmit J, et al. HIV type 1 subtype C in Addis Ababa, Ethiopia. AIDS Res Hum Retroviruses. 1997;13:1071-1075.
48. Hussein M, Abebe A, Pollakis G, et al. HIV-1 subtype C in commercial sex workers in Addis Ababa, Ethiopia. J Acquir Immune Defic Syndr. 2000;23:120-127.
49. Abebe A, Demissie D, Goudsmit J, et al. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS. 1999;13:1305-1311.
50. Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med. 1993;18:27-34.
51. Björndal Å, Sönnerborg A, Tscherning C, et al. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses. 1999;15:647-653.
52. Morris L, Cilliers T, Bredell H, et al. CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. AIDS Res Hum Retroviruses. 2001;17:697-701.